FULC shares are collapsing approximately 51% in premarket trading on June 2, 2026, from a prior close of $6.42 to a premarket price near $3.16. The sole and decisive catalyst is the company's announcement that it is permanently discontinuing its lead drug candidate, pociredir, for sickle cell disease after the FDA concluded there is no viable regulatory path forward due to malignancy risk concerns tied to the drug's mechanism of action.
CELC shares are falling sharply in premarket trading on June 2, 2026, declining approximately 22% from the prior session's close of $126.18, implying a premarket price near $98.42. The primary catalyst is the full detailed data presentation from the PIK3CA mutant cohort of Celcuity's Phase 3 VIKTORIA-1 clinical trial, delivered at the ASCO Annual Meeting in Chicago on June 2 — a long-anticipated event that appears to have triggered a "sell the news" reaction.
OCS shares plunged approximately 34.64% in after-hours and premarket trading on Monday, June 1, 2026, to around $14.84 from a prior regular-session close of $22.70 on May 29. The primary catalyst is the catastrophic failure of OCS-01, the company's lead drug candidate, in both Phase 3 DIAMOND-1 and DIAMOND-2 clinical trials in diabetic macular edema (DME).
Fate Therapeutics (FATE) stock rose approximately +129% over the past 30 days, driven primarily by positive clinical pipeline updates and a first-quarter earnings beat. Over the past quarter, the stock advanced roughly +92%, reflecting sustained momentum from biotech sector developments and company-specific progress in cellular immunotherapies.
Fate Therapeutics (FATE) stock rose approximately +129% over the past 30 days, driven primarily by positive clinical pipeline updates and a first-quarter earnings beat. Over the past quarter, the stock advanced roughly +92%, reflecting sustained momentum from biotech sector developments and company-specific progress in cellular immunotherapies.
NanoViricides (NNVC) stock rose approximately 46% over the past 30 days, driven by increased trading volume and positive momentum in clinical-stage biotech developments. Over the past quarter, the stock advanced more than 80%, reflecting broader recovery from earlier lows amid ongoing pipeline progress.
Equillium, Inc. (EQ) exhibits a prevailing uptrend on multiple timeframes, supported by positive technical ratings.
EQ stock rose approximately +39% over the past 30 days, driven by a series of positive clinical updates and analyst actions. Over the past quarter, the stock advanced more than +60%, reflecting sustained momentum from financing and development milestones.
OCS shares fell sharply, declining approximately 23.42% from the prior session close of $29.65 to a latest available price near $22.71. The decline occurred amid potential selling pressure from a large share registration filing allowing resale by certain securityholders.
Northwest Biotherapeutics continues to build its dendritic cell vaccine platform with new strategic and operational support. Recent appointments and facility expansions aim to strengthen clinical and manufacturing capabilities for DCVax therapies.
Shares of APGE are down approximately 11% in premarket trading on May 27, 2026, from a prior close of approximately $81.16 to around $72.23. The primary catalyst is the release of Phase 2 APEX Part B 16-week data for zumilokibart (APG777) in moderate-to-severe atopic dermatitis, which met primary and secondary endpoints but appeared to fall short of elevated investor expectations built up by prior trial readouts.
INSM stock declined approximately 24% over the past 30 days amid post-earnings volatility and lingering effects from an earlier clinical trial setback. Over the past quarter, the stock fell roughly 30%, driven by a combination of trial discontinuation news and cautious investor reaction to first-quarter results.
REGN stock declined approximately 15% over the past 30 days amid disappointing clinical trial results for an experimental cancer drug and subsequent analyst downgrades. Over the past quarter, the stock fell about 19%, reflecting broader pressures from mixed first-quarter 2026 earnings and sector sentiment.
NGEN shares are tumbling approximately 38% in Friday premarket trading, last changing hands near $2.28, down from the prior session's closing price of $3.68. The primary driver is a sharp negative market reaction following the company's Q1 2026 earnings release on May 18, which disclosed that NervGen is concluding enrollment in the subacute tetraplegia cohort of its Phase 1b/2a CONNECT SCI study — a pipeline contraction that caught investors off guard.
SLS shares plunged approximately 19.5% in today’s session, closing near $7.22 after the prior session’s close of $8.97. No single company-specific news event triggered the decline; the move reflects typical volatility in a pre-readout biotech stock.
NBTX shares fell approximately 8.09% to $42.47 from the prior session close of $46.20. The decline followed recent positive clinical updates and appears driven by profit-taking in a high-volatility biotech name.
Roivant Sciences is set to report results for the fourth quarter and fiscal year ended March 31, 2026. Analysts expect continued focus on clinical progress across the company’s pipeline of biopharmaceutical assets.
Shares of GENB are declining approximately 13.00% on Monday, May 18, 2026, falling from a Friday, May 15 close of $16.00 to approximately $13.92 — a sharp selloff at precisely the stock's IPO price of $16.00, where technical and psychological resistance triggered profit-taking from investors who had been holding since the biotech's February 27, 2026 Nasdaq debut and are now exiting at breakeven levels.
Shares of REGN are trading down approximately 12% in Monday's session following a late-Friday clinical trial disclosure. The primary catalyst is the failure of fianlimab, Regeneron's experimental LAG-3 inhibitor, in a pivotal Phase 3 trial for first-line unresectable or metastatic melanoma.
Quarterly revenue remained at $0, reflecting a pre‑commercial stage company. Net loss expanded to $79.2 million (‑$0.52 per ADS), driven by higher R&D expense.